Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00122629|
Recruitment Status : Terminated
First Posted : July 22, 2005
Last Update Posted : July 29, 2005
Triple antiviral therapy with peg-interferon-alfa/ribavirin+amantadine was suggested to increase sustained virological response (SVR) rates in HCV non-responders to a standard interferon/ribavirin combination.
Patients with hepatitis C virus infection were eligible if they had failed to respond to a single previous 24 week cycle of interferon/ribavirin combination therapy. Non-response was defined as persistent HCV RNA in the serum during the last month of treatment.
This study tested the efficacy and safety of pegylated interferon alfa-2b with ribavirin and amantadine or a placebo for 48 weeks.
|Condition or disease||Intervention/treatment||Phase|
|Hepatitis C, Chronic||Drug: peg-interferon alfa-2b Drug: ribavirin Drug: amantadine||Phase 3|
Triple antiviral therapy with peg-interferon-alfa/ribavirin + amantadine was suggested to increase sustained virological response (SVR) rates in HCV non-responders to a standard interferon/ribavirin combination.
The aim of this study is to determine if the addition of amantadine to PEG-IFN/ribavirin enhances SVR.
This study is a double blind, comparative, prospective multicenter, randomized study. Patients are recruited from 23 hepatology centers in France. The protocol was approved by the French ethical committee and all patients provided written informed consent. Eligible subjects are randomly assigned to the two treatment groups in equal proportions. The randomization process is generated by the Department of Biostatistics, Hospices Civils de Lyon, Lyon, France.
Main inclusion criteria are: elevated ALT, detectable HCV RNA, Metavir score over or equal to A1F1 and below or equal to F3. Patients received PEG-IFN 1.5µg/kg/week, ribavirin 800-1200mg/day and amantadine 200mg/day or placebo during 48 weeks.
The primary endpoint is a sustained virological response, defined as an undetectable HCV-RNA 24 weeks after treatment discontinuation (week 72). Secondary endpoints are the biochemical response at week 72 defined as ALT normalization; histological benefit; tolerance; and virological and biochemical responses during therapy at weeks 12, 24 and 48.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||405 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous HCV Non Responders ANRSHC03 BITRI|
|Study Start Date :||October 2000|
|Study Completion Date :||May 2003|
- Sustained virological response, defined as an undetectable HCV-RNA 24 weeks after treatment discontinuation at week 72
- Biochemical response at week 72 defined as ALT normalization
- Histological benefit
- Virological and biochemical responses during therapy at weeks 12, 24 and 48
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00122629
|Service d'Hépato-Gastroentérologie Hopital Hotel Dieu|
|Lyon Cedex, France, 69288|
|Principal Investigator:||Christian Trepo, MD||Hépato-Gastroentérologie Hopital Hôtel-Dieu LYON|
|Study Chair:||P. ADELEINE, MD||Laboratoire d'Informatique Médicale Lyon|